Edition:
United States

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

350.10DKK
10:59am EDT
Change (% chg)

kr.6.40 (+1.86%)
Prev Close
kr.343.70
Open
kr.343.70
Day's High
kr.351.30
Day's Low
kr.343.70
Volume
617,067
Avg. Vol
376,602
52-wk High
kr.363.40
52-wk Low
kr.212.70

Latest Key Developments (Source: Significant Developments)

H Lundbeck Q3 EBIT DKK 589 million, beats expectations
Wednesday, 2 Nov 2016 02:47am EDT 

H Lundbeck A/S : Q3 revenue 3.95 billion Danish crowns ($587.5 million)(Reuters poll 3.71 billion crowns) . Q3 EBIT 589 million crowns (Reuters poll 449 million crowns) . Sees profit from operations (EBIT) to reach 2.1 billion-2.3 billion crowns for 2016 .Now expects 2016 revenue to reach 15.3 billion-15.7 billion crowns.  Full Article

Lundbeck says alzheimer's drug late stage study fails
Thursday, 22 Sep 2016 12:01pm EDT 

H Lundbeck A/S : In first study, idalopirdine did not meet primary endpoint . Conclusions from first out of three phase 3 studies on idalopirdine in alzheimer's disease . Idalopirdine was safe and well tolerated .Two remaining studies, Starbeam and StarbrightII in phase 3 programme will continue as planned, data expected in first quarter of 2017.  Full Article

Lundbeck Q2 EBIT beats expectations; raises FY outlook
Wednesday, 24 Aug 2016 01:51am EDT 

H Lundbeck A/S : Q2 revenue 3.75 billion Danish crowns ($568.8 million) (Reuters poll 3.67 billion crowns) . Q2 EBIT 469 million crowns (Reuters poll 414 million crowns) . Now expects 2016 revenue of around 14.6 billion - 15.0 billion crowns compared to previously 14.2 billion - 14.6 billion crowns .2016 EBIT is expected to reach 1.5 billion - 1.7 billion crowns compared to 1.3 billion - 1.5 billion crowns.  Full Article

Lundbeck: Trintellix (vortioxetine) now available in US
Wednesday, 1 Jun 2016 10:29am EDT 

H Lundbeck A/S : Says Trintellix (vortioxetine) is now available in US . Says trade name for the vortioxetine product in US would be changed to Trintellix to avoid name confusion .Says formulation, indication and dosages of Trintellix remain the same as that of Brintellix.  Full Article

H Lundbeck Q1 EBIT 483 million; beats expectations
Wednesday, 11 May 2016 01:57am EDT 

H Lundbeck A/S : Q1 revenue 3.77 billion Danish crowns ($576.96 million) (Reuters poll 3.62 billion crowns) . Q1 EBIT 483 million crowns (Reuters poll 254 million crowns) . 2016 guidance raised based on solid sales performance and improved profitability .Now expects revenue of around 14.2-14.6 billion crowns and EBIT is expected to reach 1.3-1.5 billion crowns for 2016 compared to previously 13.8-14.2 billion crowns and 1.0-1.2 billion crowns, respectively.  Full Article

H Lundbeck A/S says Board elected Lars Rasmussen as Chairman
Thursday, 31 Mar 2016 07:32am EDT 

H Lundbeck A/S:Says Board of Directors has elected Lars Rasmussen as Chairman.  Full Article

H Lundbeck and Takeda receive complete response letter by FDA for Brintellix (vortioxetine) sNDA
Tuesday, 29 Mar 2016 01:00am EDT 

H Lundbeck A/S:Says the company and Takeda receive complete response letter (CRL) by the U.S. Food and Drug Administration (FDA) for Brintellix (vortioxetine) supplemental new drug application (sNDA).FDA issued CRL for sNDA to include new data in clinical trials section of US label of Brintellix (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with major depressive disorder (MDD).Complete response letter does not apply to use of Brintellix in MDD.Says is disappointed with response given that US FDA Psychopharmacologic Drugs Advisory Committee (PDAC) voted 8 to 2 that Takeda and Lundbeck presented substantial evidence to support a claim of effectiveness for Brintellix in treating certain aspects of cognitive dysfunction in adults with MDD.Parties look forward to reviewing the contents of the letter with the FDA to determine the appropriate path forward Source text for Eikon.  Full Article

H Lundbeck A/S starts clinical phase III program with Lu AF35700
Friday, 11 Mar 2016 05:34am EST 

H Lundbeck A/S:Says starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia.First study is planned to enroll about 1,000 patients in about 15 countries including U.S. and Canada and is expected to last around three years ‍.Lu AF35700 has been granted fast track designation in treatment resistant schizophrenia by FDS​.  Full Article

H Lundbeck proposes no FY 2015 dividend; gives FY 2016 guidance
Wednesday, 10 Feb 2016 01:46am EST 

H Lundbeck A/S:For FY 2015 the board of directors proposes no dividend payout​.For FY 2016 expects revenue of around 13.8-14.2 billion Danish crowns.For FY 2016 EBIT is expected to reach 1.0-1.2 billion crowns​.FY 2016 revenue 13.90 billion crowns - Thomson Reuters I/B/E/S.  Full Article

H Lundbeck A/S provides update on effectiveness for Brintellix
Thursday, 4 Feb 2016 01:02am EST 

H Lundbeck A/S:Evidence has been presented to support a claim of effectiveness for Brintellix for treating certain aspects of cognitive dysfunction in MDD​.Panel discussed that cognitive dysfunction in MDD represents an appropriate drug development target​.  Full Article

More From Around the Web

UPDATE 1-Lundbeck raises earnings guidance for the fourth time in 12 months

May 10 Danish drugmaker Lundbeck raised its financial guidance for the fourth time in 12 months as sales of its anti-epileptic drug Sabril was not dented by copycat competition, as Lundbeck had expected, its chief executive said on Wedneday.